Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel lipid-regulating drugs.

G R Thompson1, R P Naoumova

  • 1Division of Investigative Science, Imperial College School of Medicine and MRC Molecular Medicine Group, MRC Clinical Sciences Centre, Hammersmith Hospital, London, UK. g.thompson@ic.ac.uk

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicenter Registry of Patients Receiving Systemic Mold-Active Triazoles for the Management of Invasive Fungal Infections.

Infectious diseases and therapy·2022
Same author

Coccidioidomycosis in llamas and alpacas diagnosed at the University of California, Davis (1990-2016).

Medical mycology·2020
Same author

Ibrexafungerp: A novel oral glucan synthase inhibitor.

Medical mycology·2019
Same author

A microbiome assessment of medical marijuana.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2016
Same author

The Nobel dilemma: to reward scientific discovery or benefit to mankind?

QJM : monthly journal of the Association of Physicians·2015
Same author

Dyslipidaemia and the military patient.

Journal of the Royal Army Medical Corps·2015
Same journal

Targeting fatty acid synthase inhibitors for the treatment of acne vulgaris: what can we learn from early phase investigations.

Expert opinion on investigational drugs·2026
Same journal

Elezanumab for the treatment of spinal cord injury: assessing the clinical development journey to date.

Expert opinion on investigational drugs·2026
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
See all related articles

Recent advancements in lipid-regulating drugs focus on lowering low-density lipoprotein (LDL) cholesterol. Future developments may shift towards increasing high-density lipoprotein (HDL) cholesterol levels.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Lipid regulation is crucial for cardiovascular health.
  • Dyslipidemia, characterized by abnormal lipid levels, is a major risk factor for heart disease.
  • Current therapeutic strategies primarily target lowering low-density lipoprotein (LDL) cholesterol.

Purpose of the Study:

  • To review major developments in lipid-regulating drugs over the past two years.
  • To highlight novel compounds for lowering LDL cholesterol.
  • To explore emerging targets for modulating high-density lipoprotein (HDL) cholesterol.

Main Methods:

  • Literature review of recent pharmaceutical developments.
  • Analysis of preclinical and clinical data for lipid-modulating agents.

Related Experiment Videos

  • Examination of recent discoveries in lipoprotein metabolism.

    • Main Results:

    • Several novel compounds targeting LDL cholesterol reduction are in late-stage development or have been launched, including bile acid sequestrants, HMG-CoA reductase inhibitors, and cholesterol absorption inhibitors.
    • Preclinical studies show promise for orally bioavailable inhibitors of cholesterol ester transfer protein (CETP) and acyl-CoA:cholesterol acyltransferase (ACAT).
    • New insights into scavenger receptor class B Type 1 (SR-B1) and ATP-binding cassette transporter 1 (ABC-A1) roles in HDL transport suggest a potential shift in therapeutic focus.

    Conclusions:

    • The current trend in lipid-regulating drug development is predominantly focused on lowering LDL cholesterol.
    • Emerging research on HDL cholesterol metabolism may lead to future therapies aimed at increasing HDL levels.
    • The field is evolving towards more comprehensive strategies for lipid management, potentially combining LDL reduction with HDL elevation.